Huadong Medicine (000963.SZ): Positive topline results from the Phase III weight-loss study of HDM1002 tablets, an innovative oral small-molecule GLP-1 receptor agonist

Zhitong Finance APP News, Huadong Medicine (000963.SZ) announced that recently, the China Phase III clinical study (HDM1002-301) of HDM1002 tablets, a Class 1 innovative drug and oral small-molecule GLP-1 receptor agonist independently developed by the company's wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., for weight management in overweight or obese populations, achieved positive topline results.